Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY - van der Lely, A. J.; Biller, Beverly M. K.; Brue, Thierry; Buchfelder, Michael; Ghigo, Ezio; Gomez, Roy; Hey-Hadavi, Judith; Lundgren, Frida; Rajicic, Natasa; Strasburger, Christian J.; Webb, Susan M.; Kołtowska-Häggström, Maria (The journal of clinical endocrinology and metabolism, 2012)
Keywords: Acromegaly - drug therapy; Acromegaly - etiology; Adolescent; Adult; Aged; Aged, 80 and over; Biological and medical sciences; Child; Child, Preschool; Endocrinopathies; Feeding. Feeding behavior; Female; Follow-Up Studies; Fundamental and applied biological sciences. Psychology; Hormone Antagonists - adverse effects; Hormone Antagonists - therapeutic use; Human Growth Hormone - adverse effects; Human Growth Hormone - analogs & derivatives; Human Growth Hormone - therapeutic use; Humans; Hypothalamus. Hypophysis. Epiphysis (diseases); Infant; Liver Function Tests; Male; Medical sciences; Middle Aged; Non tumoral diseases. Target tissue resistance. Benign neoplasms; Pituitary Neoplasms - complications; Pituitary Neoplasms - drug therapy; Product Surveillance, Postmarketing; Receptors, Somatotropin - antagonists & inhibitors; Treatment Outcome; Vertebrates: anatomy and physiology, studies on body, several organs or systems; Vertebrates: endocrinology; Endocrinopathy; Human; Obesity; Nutrition; Pegvisomant; Toxicity; Diseases of the osteoarticular system; Nutrition disorder; Acromegaly; Patient; Metabolic diseases; Review; Long term; Somatotropin; Adenohypophyseal hormone; Pituitary diseases; Antagonist; Safety; Endocrinology; Nutritional status; Bibliographic review